HDAC3 and lymphoma: These findings suggest that HDAC3 pharmacologic inhibition can be a promising therapeutic strategy for CREBBP-mutant GCB lymphomas, promoting GC B-cell exit and differentiation into PCs (Mondello et al., 2020).